Table 17.
Efficacy of 60 mg daclatasvir + 400 mg sofosbuvir QD with or without ribavirin for 12 weeks.
| Cirrhosis | Prior treatment | SVR12 rate |
Study and trial phase | Ref. | ||
|---|---|---|---|---|---|---|
| GT-1 | GT-2 | GT-3 | ||||
| 60 mg daclatasvir + 400 mg sofosbuvir QD for 12w | ||||||
| No cirrhosis | Naïve | 100% (35/35) | A1444040, phase 3 | Sulkowski et al., 2014a | ||
| Naïve | 97.3% (73/75) | ALLY-3, phase 3 | Nelson et al., 2015 | |||
| Experienced | 94.1% (32/34) | |||||
| Experienced or naive | ? | ? | ANRS CO23 CUPILT | Coilly et al., 2016 | ||
| Naïve | 100% (25/25) | ANRS/AFEF Hepather | Pol et al., 2017 | |||
| Experienced | 97.6% (40/41) | |||||
| Cirrhosis |
Naïve | 100% (6/6) | AI444040, phase 3 | Sulkowski et al., 2014a | ||
| Naïve | 1a: 83.3% (5/6), 1b: 100% (1/1) | ALLY-1, phase 3 | Poordad et al., 2016a | |||
| Experienced | 1a: 100% (7/7), 1b: 100% (2/2) | |||||
| Naïve | 57.9% (11/19) | ALLY-3, phase 3 | Nelson et al., 2015 | |||
| Experienced | 69.2% (9/13) | |||||
| Experienced or naive | ? | ? | ANRS CO23 CUPILT | Coilly et al., 2016 | ||
| Naïve | 79.5% (31/39) | ANRS/AFEF Hepather | Pol et al., 2017 | |||
| Experienced | 92.8% (51/55) | |||||
| Experienced | 66.7% (2/3) a | 40% (2/5) a | Real-world study | Cheung et al., 2016 | ||
| 60 mg daclatasvir + 400 mg sofosbuvir QD + ribavirin for 12w | ||||||
| No cirrhosis | Naïve | 1a:100% (8/8), 1b:100% (1/1) | 100% (5/5) | ALLY-1, phase 3 | Poordad et al., 2016a | |
| Experienced | 1a:100% (10/10), 1b:100% (5/5) | 83.3% (5/6) | ||||
| Experienced | 100% (2/2) | ALLY-3+, phase 3 | Leroy et al., 2016 | |||
| Naïve | 100% (4/4) | |||||
| Naïve | ?/36 | A1444040, phase 3 | Sulkowski et al., 2014a | |||
| Naïve | 100% (1/1) | ANRS/AFEF Hepather | Pol et al., 2017 | |||
| Experienced | 100% (8/8) | |||||
| Naïve | 100% (5/5) | Real-world study | Mangia et al., 2016 | |||
| Experienced | 100% (3/3) | |||||
| Cirrhosis | Naïve | 50% (1/2) | ALLY-3+, phase 3 | Leroy et al., 2016 | ||
| Experienced | 87.5% (14/16) | |||||
| Naïve | 100% (2/2) | ANRS/AFEF Hepather | Pol et al., 2017 | |||
| Experienced | 91.3% (21/23) | |||||
| Naïve | ?/5 | A1444040, phase 3 | Sulkowski et al., 2014a | |||
| Experienced | 88.2% (30/34) a | 69.2% (72/104)a | Real-world study | Cheung et al., 2016 | ||
?: Question marks indicate that the data was unavailable.
a
SVR24 rates were used in the study.